78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

• Yun Zhang,
• Jian Huang,
• Pei Zhang,
• Hanzhong Li,
• Ruiqi Huang,
• Wei Shen,
• Aiping Zhou,
• Dingwei Ye,
• Xiaopeng Ma,
• Qing Zou,
• Cheng Fu,
• Hailong Hu,
• Xiusong Qiu,
• Lilin Zhang,
• Feng Bi

Affiliations

Yun Zhang

1 Clinical Medicine Department, Fujian Health College, Fuzhou, China

Jian Huang

Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Pei Zhang

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Hanzhong Li

4Peking Union Medical College Hospital, Beijing, China

Ruiqi Huang

8BeiGene (Beijing) Co., Ltd., Beijing, China

Wei Shen

1 Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA

Aiping Zhou

10 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Dingwei Ye

11 Department of Urology, Fudan University Shanghai Cancer, Shanghai, China

Xiaopeng Ma

7Beigene (Beijing) Co., Ltd., Beijing, China

Qing Zou

3Jiangsu Cancer Hospital, Nanjing, China

Cheng Fu

5Liaoning Cancer Hospital and Institute, Shenyang, China

Hailong Hu

6Second Hospital Tianjin Medical University, Tianjin, China

Xiusong Qiu

8BeiGene (Beijing) Co., Ltd., Beijing, China

Lilin Zhang

8BeiGene (Beijing) Co., Ltd., Beijing, China

Feng Bi

9West China Hospital, Sichuan University, Changdu, China